Pear Therapeutics Launches Somryst Insomnia App Via an End-to-End Virtual Care Experience

 Pear Therapeutics Launches Somryst Insomnia App Via an End-to-End Virtual Care Experience

Pear Therapeutics Launches Somryst Insomnia App Via an End-to-End Virtual Care Experience

Shots:

  • Pear Therapeutics launches Somryst as the first PDT intended for use in the treatment of patients with chronic insomnia aged > 22yrs. It addresses the issues of chronic insomnia by delivering (CBTi) approach that trains the brain and body to sleep
  • In a study of ~1,400 adults with CI, PDT reduced the amount of time it took to fall asleep (45%), reduced the amount of time spent awake at night (52%) and reduced severity of insomnia symptoms (45%) with continued improvement at 6 & 12 mos. post-treatment
  • Somryst will be promoted via a fully virtual experience, combining telemedicine visits and PDT prescribing and dispensation via PearConnect

Click here ­to­ read full press release/ article | Ref: Pear therapeutics | Image: MobileHealthNews

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post